Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Androgen Receptor Antagonists Approach Primetime for Breast Cancer
Existing data for androgen receptor (AR) antagonists are encouraging and anticipated future results could soon show a benefit for these agents in large populations of patients with breast cancer.
Friedewald Explains Benefits, Limitations of Tomosynthesis for Breast Cancer Screening
Radiologists have been challenged by the ever-changing recommendations of when breast cancer screening should begin and the frequency of screening, says Sarah M. Friedewald, MD. The controversy surrounding screening recommendations can be a distraction to the implementation of new technologies, such as tomosynthesis.
Why Nomograms Provide Optimal Risk Assessment of Recurrent DCIS
Kimberly J. Van Zee, MS, MD, FACS, presented her findings on the benefits of nomogram during a panel on “Breast Pathology for the Non-Pathologist” at the 18th annual Lynn Sage Breast Cancer Symposium in Chicago.
Experts Explain Intricacies of Image-Directed Breast Core Biopsies
The selection process for determining which procedure to utilize for an image-directed core breast biopsy often remains a mystery to those outside of the pathology and radiology world.
More Strategies Needed to Overcome Resistance, Progression in HR-Positive Breast Cancer
William J. Gradishar, MD, discusses combining and sequencing novel targeted therapies.
View More >


Mesa Provides Tips for Treating Myelofibrosis After Ruxolitinib
Mesa Provides Tips for Treating Myelofibrosis After Ruxolitinib
Developing a treatment plan for myelofibrosis patients who fail ruxolitinib requires an understanding of both current treatment options and those that are expected to become available within the next several years.
Immunotherapy May Be Next Frontier for AML, Says Daver
Immunotherapy offers promise in acute myeloid leukemia (AML), a disease type which has not seen significant progress in many years, said Naval G. Daver, MD
Blinatumomab Receives FDA Approval for Acute Lymphoblastic Leukemia
Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
NDA for Neratinib in HER2-Positive Breast Cancer Accepted by FDA
A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer
Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer